Akero Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Published results from the 96-Week Phase 2b SYMMETRY trial in the New England Journal of Medicine Three presentations at the EASL Congress 2025 highlighted data demonstrating statistically significant reversal of compensated cirrhosis (F4) due to MASH and corroborating the anti-fibrotic activity of EFX seen in patients with pre-cirrhotic (F2-F3) MASH Cash, cash equivalents and short and long-term marketable securities of $1,086.2 million at June 30, 2025 SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEW ...